Literature DB >> 23634397

The Patients' Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter pylori Eradication Regimens.

Mohammad Abbasinazari1, Zahra Sahraee, Maryam Mirahmadi.   

Abstract

BACKGROUND: Helicobacter pylori is a major cause of upper gastrointestinal disorders. The eradication of H. pylori has been recommended for the treatment of different gastrointestinal diseases. Notwithstanding, a combination therapy is needed for Helicobacter pylori eradication, but using these medications can be the cause, the incidence risk of patients' adherence to treatment regimens reduction and probably increase risk of Adverse Drug Reactions (ADRS), so, it is seem that evaluation the out come of combination therapy is need more than the past. AIM: The aim of present study was to determine the patients' adherence to the treatment and the ADRs with five eradiation regimens. SETTING AND
DESIGN: A cross sectional study was done in a well known referral clinic of gastrointestinal disorders in Tehran, Iran. METHODS AND MATERIALS: Ninety patients were evaluated the study (18 in each of the five regimens). The adherence to the treatment and the ADRs of the patients were asked during the treatment, twice, by doing telephone assays. STATISTICAL ANALYSIS USED: The data were analyzed by using the SPSS, 17 software and the statistical significance was accepted for the P values of 0.05.
RESULTS: 81% of the patients had a good adherence and there was no significant difference between the types of regimens (triple or quadruple therapy) and the adherence to the treatment regimens by the patients (p=0.6). Also, we found that there was no significant relationship between the types of regimens and the sex (p=0.99), education level (p=0.99), accommodation (p=0.93), an existence of underlying disease (p=0.86) and the concurrent use other medications (p=0.93). But there was a significant relationship between the patients' age and adherence to the treatment regimens (p=0.008). The most reported ADRs belonged to gastrointestinal (GI) disorders (an abnormal taste had the most prevalence (36.6%) among the GI disorders). There was no significant relationship between the regimen type and the GI ADRs, (p=0.48).
CONCLUSION: The findings of this study showed that the patients' adherence to the treatment regimens and the ADRs did not have a significant relationship with the various eradication regimens for H. pylori. It seems that the type of H. pylori eradication regimen may not be an important factor in the patients' adherence to the treatment regimens and the ADRs.

Entities:  

Keywords:  Adherence; Adverse drug reactions; Helicobacter pylori; Patients

Year:  2013        PMID: 23634397      PMCID: PMC3616557          DOI: 10.7860/JCDR/2013/4673.2799

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

3.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

4.  Predictors of medication noncompliance in a sample of older adults.

Authors:  S J Coons; S L Sheahan; S S Martin; J Hendricks; C A Robbins; J A Johnson
Journal:  Clin Ther       Date:  1994 Jan-Feb       Impact factor: 3.393

Review 5.  Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.

Authors:  P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

6.  Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.

Authors:  L A Fischbach; S van Zanten; J Dickason
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

Review 7.  Adherence to treatment and health outcomes.

Authors:  R I Horwitz; S M Horwitz
Journal:  Arch Intern Med       Date:  1993-08-23

Review 8.  Helicobacter pylori eradication: role of individual therapy constituents and therapy duration.

Authors:  Asghar Qasim; Colm A O'Morain; Humphrey J O'Connor
Journal:  Fundam Clin Pharmacol       Date:  2009-01-10       Impact factor: 2.748

Review 9.  New strategies for Helicobacter pylori eradication.

Authors:  Michael Selgrad; Peter Malfertheiner
Journal:  Curr Opin Pharmacol       Date:  2008-06-12       Impact factor: 5.547

10.  Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.

Authors:  Bruno Sanches; Luiz Coelho; Luciana Moretzsohn; Gerival Vieira
Journal:  Helicobacter       Date:  2008-12       Impact factor: 5.753

View more
  6 in total

1.  Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010-2019.

Authors:  Inés Ariño Pérez; Samuel J Martínez-Domínguez; Enrique Alfaro Almajano; Patricia Carrera-Lasfuentes; Ángel Lanas
Journal:  Antibiotics (Basel)       Date:  2022-05-20

2.  Buccal Buspirone as add-on Therapy to Omeprazole Versus Omeprazole in Treatment of Gastroesophageal Reflux Diseases (GERD).

Authors:  Saeed Abdi; Zahra Sargashteh; Mohammad Abbasinazari; Jamshid Salamzadeh; Seyed Alireza Mortazavi
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

3.  Design and synthesis of new N-thioacylated ciprofloxacin derivatives as urease inhibitors with potential antibacterial activity.

Authors:  Keyvan Pedrood; Homa Azizian; Mohammad Nazari Montazer; Ali Moazzam; Mehdi Asadi; Hamed Montazeri; Mahmood Biglar; Mozhdeh Zamani; Bagher Larijani; Kamiar Zomorodian; Maryam Mohammadi-Khanaposhtani; Cambyz Irajie; Massoud Amanlou; Aida Iraji; Mohammad Mahdavi
Journal:  Sci Rep       Date:  2022-08-15       Impact factor: 4.996

Review 4.  A Comprehensive Review of the Role of Complementary and Dietary Medicines in Eradicating Helicobacter pylori.

Authors:  Saeed Abdi; Sara Ataei; Maede Abroon; Pantea Majma Sanaye; Mohammad Abbasinazari; Amir Farrokhian
Journal:  Iran J Pharm Res       Date:  2022-06-18       Impact factor: 1.962

5.  Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials.

Authors:  Jianglong Shi; Liyun Liu; Jian Li; Xiaoju Ma; Hairong Qiu; Tao Shen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

6.  Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.

Authors:  Endalew Gebeyehu; Desalegn Nigatu; Ephrem Engidawork
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.